Results 151 to 160 of about 39,319 (333)

Cost-effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia in older adults without deletion 17p

Blood Advances, 2018
: Ibrutinib is a novel oral therapy that has shown significant efficacy as initial treatment of chronic lymphocytic leukemia (CLL). It is a high-cost continuous therapy differing from other regimens that are given for much shorter courses.
James I. Barnes, Vasu Divi, Adrian Begaye, Russell Wong, Steven Coutre, Douglas K. Owens, Jeremy D. Goldhaber-Fiebert   +6 more
doaj  

A case of CNS aspergillosis in a patient with chronic lymphocytic leukemia on first-line ibrutinib therapy

Medical Mycology Case Reports, 2020
Ibrutinib has revolutionized the treatment of chronic lymphoid malignancies. Despite its success, ibrutinib has been linked with several reports of invasive fungal infections.
Emily M. Eichenberger, Jennifer Saullo, Danielle Brander, Shih-Hsiu Wang, John R. Perfect, Julia A. Messina   +5 more
doaj  

Extended follow-up and impact of high-risk prognostic factors from the phase 3 RESONATE(TM) study in patients with previously treated CLL/SLL. [PDF]

, 2018
In the phase 3 RESONATE(TM) study, ibrutinib demonstrated superior progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) compared with ofatumumab in relapsed/refractory CLL patients with high-risk prognostic factors.
Brown, JR, Hillmen, P, O'Brien, S, Barrientos, JC, Reddy, NM, Coutre, SE, Tam, CS, Mulligan, SP, Jaeger, U, Barr, PM, Furman, RR, Kipps, TJ, Cymbalista, F, Thornton, P, Caligaris-Cappio, F, Delgado, J, Montillo, M, DeVos, S, Moreno, C, Pagel, JM, Munir, T, Burger, JA, Chung, D, Lin, J, Gau, L, Chang, B, Cole, G, Hsu, E, James, DF, Byrd, JC   +29 more
core   +1 more source

Endotypes in Immune Mediated Drug Reactions: Present and Future of Relevant Biomarkers. An EAACI Task Force Report

Allergy, EarlyView.
ABSTRACT Drug‐induced immune reactions are an important burden for patients and health systems. They can be classified into immediate‐drug hypersensitivity reactions (IDHRs) and delayed‐DHRs (DDHRs) based on their phenotype. Drugs do not always behave as allergens and need to bind to proteins, forming adducts.
C. Mayorga, R. Fernandez‐Santamaria, G. E. Çelik, M. Labella, G. Murdaca, M. Sokolowska, D. Naisbitt, V. Sabato   +7 more
wiley   +1 more source

Basophil Activation Test: Bridging Allergy and Oncology for Diagnostic, Therapeutic and Prognostic Applications in AllergoOncology: An EAACI Position Paper

Allergy, EarlyView.
ABSTRACT The basophil activation test (BAT) is gaining increasing relevance as an ex vivo functional assay in allergy to evaluate IgE‐mediated hypersensitivity reactions to food allergens, venoms, and drugs and to monitor tolerance induction. Establishing universal standard operating protocols has been difficult, due to several challenges including ...
Mariona Pascal, Jitesh Chauhan, Edward Knol, Rodolfo Bianchini, Mariana Castells, Leticia De las Vecillas, Karin Hartmann, Elena Izquierdo, Uta Jappe, Teodorikez‐Wilfox Jimenez‐Rodriguez, Francesca Levi‐Schaffer, Cristobalina Mayorga, Aurélie Poli, Frank Redegeld, Alexandra F. Santos, Erika Jensen‐Jarolim, Christoph Bergmann, Sophia N. Karagiannis, Heather J. Bax   +18 more
wiley   +1 more source

Activation of MYC, a bona fide client of HSP90, contributes to intrinsic ibrutinib resistance in mantle cell lymphoma

Blood Advances, 2018
: The BTK inhibitor ibrutinib has demonstrated a remarkable therapeutic effect in mantle cell lymphoma (MCL). However, approximately one-third of patients do not respond to the drug initially.
Jimmy Lee, Liang Leo Zhang, Wenjun Wu, Hui Guo, Yan Li, Madina Sukhanova, Girish Venkataraman, Hui Zhang, Mir Alikhan, Pin Lu, Ailin Guo, Natalie Galanina, Jorge Andrade, Michael L. Wang, Y. Lynn Wang   +14 more
doaj  

Bruton Tyrosine Kinase Inhibitor Ibrutinib (PCI-32765) Has Significant Activity in Patients With Relapsed/Refractory B-Cell Malignancies [PDF]

, 2012
Ranjana H. Advani, Joseph J. Buggy, Jeff P. Sharman, Sonali M. Smith, Thomas E. Boyd, Barbara Grant, Kathryn S. Kolibaba, Richard R. Furman, Sara Rodríguez, Betty Chang, Juthamas Sukbuntherng, Raquel Izumi, Ahmed Hamdy, Eric Hedrick, Nathan Fowler   +14 more
openalex   +1 more source

Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia.

New England Journal of Medicine, 2014
BACKGROUND In patients with chronic lymphoid leukemia (CLL) or small lymphocytic lymphoma (SLL), a short duration of response to therapy or adverse cytogenetic abnormalities are associated with a poor outcome.
J. Byrd, Jennifer R. Brown, S. O'brien, J. Barrientos, N. Kay, N. Reddy, S. Coutre, C. Tam, S. Mulligan, U. Jaeger, S. Devereux, P. Barr, R. Furman, T. Kipps, F. Cymbalista, C. Pocock, P. Thornton, F. Caligaris‐cappio, T. Robak, J. Delgado, S. Schuster, M. Montillo, A. Schuh, S. de Vos, D. Gill, A. Bloor, C. Dearden, C. Moreno, Jeffrey J Jones, A. Chu, M. Fardis, J. Mcgreivy, F. Clow, D. James, P. Hillmen   +34 more
semanticscholar   +1 more source

Simplified Molecular International Prognostic Index as an eligibility criterion for clinical trials: Analysis of the Turkish Lymphoma Study Group's large B‐cell lymphoma cohort

British Journal of Haematology, EarlyView.
The international prognostic index (IPI)‐driven trial inclusion criteria may have contributed to the failure of some of the first‐line trials in large B‐cell lymphoma (LBCL). GLA and LYSA collaborated to improve prognostic stratification in LBCL by analyzing data from trial cohorts and proposed the smIPI.
Umut Yılmaz, Esra Terzi Demirsoy, Fatma Keklik Karadağ, Uğur Hatipoğlu, Meral Uluköylü Mengüç, Ebru Pekgüç, Taner Tan, Eda Nuhoğlu Kantarcı, Metban Mastanzade, Ali Durdu, Merve Apaydın Kayer, Murat Özbalak, Tuğrul Elverdi, Asu Fergün Yılmaz, Deniz Gören, Tayfur Toptaş, Turgay Ulaş, Özgür Mehtap, Mehmet Sinan Dal, Olga Meltem Akay, Muhlis Cem Ar, Güray Saydam, Fevzi Altuntaş, Elif Birtaş Ateşoğlu, Burhan Ferhanoğlu   +24 more
wiley   +1 more source

Acute kidney injury after chimeric antigen receptor T‐cell therapy is associated with inferior survival in patients with relapsed/refractory large B‐cell lymphoma

British Journal of Haematology, EarlyView.
Summary Baseline risk factors for acute kidney injury (AKI) during chimeric antigen receptor T‐cell (CAR‐T) therapy are not well described. Hence, we evaluated the incidence and risk factors associated with AKI among patients undergoing CAR‐T for relapsed/refractory large B‐cell lymphoma. Among 155 patients, 28 (18%) developed AKI with a median time‐to‐
John Sharp, Qiuhong Zhao, Timothy J. Voorhees, David A. Bond, Yazeed Sawalha, John Reneau, Audrey Sigmund, Walter Hanel, Lalit Sehgal, Lapo Alinari, Robert Baiocchi, Jonathan E. Brammer, Kami Maddocks, Beth Christian, Evandro Bezerra, Nathan Denlinger, Sumithira Vasu, Marcos De Lima, Jason Prosek, Narendranath Epperla   +19 more
wiley   +1 more source